Pluronic® block copolymers as modulators of drug efflux transporter activity in the blood-brain barrier

Advanced Drug Delivery Reviews

Volumn 55, Issue 1, 2003, Pages 151-164

  Kabanov, Alexander V ^a   Batrakova, Elena V ^a   Miller, Donald W ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Block copolymer; Blood brain barrier; Multidrug resistance (MDR); Multidrug resistant protein (MRP); P glycoprotein

Indexed keywords

ABSORPTION; COPOLYMERS; MODULATORS; PHARMACODYNAMICS; PHARMACOKINETICS; TISSUE CULTURE;

THERAPEUTIC AGENTS;

DRUG PRODUCTS;

ADENOSINE TRIPHOSPHATASE; AMPHOPHILE; CARRIER PROTEIN; COPOLYMER; DIGOXIN; DOXORUBICIN; ETHYLENE OXIDE; FLUORESCEIN; GLYCOPROTEIN P; LEVODOPA; LOPERAMIDE; MANNITOL; METHOTREXATE; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL; POLOXAMER; PROPYLENE OXIDE; PROTEIN INHIBITOR; RHODAMINE 123; RITONAVIR; SP 1049C; VALPROIC ACID; VINBLASTINE; ZIDOVUDINE; ABC TRANSPORTER; AGENTS AFFECTING WATER, MOLECULE OR ION TRANSPORT; DRUG; DRUG CARRIER;

BLOOD BRAIN BARRIER; CANCER; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG FORMULATION; DRUG PENETRATION; DRUG TARGETING; DRUG TRANSPORT; NONHUMAN; PRIORITY JOURNAL; REVIEW; TOXICOLOGY; ACTIVE TRANSPORT; ANIMAL; BRAIN; DRUG ANTAGONISM; DRUG EFFECT; HUMAN; METABOLISM; VASCULAR ENDOTHELIUM; VASCULARIZATION;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL TRANSPORT, ACTIVE; BLOOD-BRAIN BARRIER; BRAIN; DRUG CARRIERS; ENDOTHELIUM, VASCULAR; HUMANS; MEMBRANE TRANSPORT MODULATORS; MEMBRANE TRANSPORT PROTEINS; P-GLYCOPROTEIN; PHARMACEUTICAL PREPARATIONS; POLOXAMER;

EID: 0037457792     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(02)00176-X     Document Type: Article

References (72)

1. Pardridge W.M. Introduction to the Blood-Brain Barrier. Methodology, Biology and Pathology. 1998;University Press, Cambridge. pp. 486.
2. Miller D.W., Kabanov A.V. Potential applications of polymers in the delivery of drugs to the central nervous system. Colloids Surf. B: Biointerfaces. 16:1999;321-330.
3. Alakhov V.Y., Moskaleva E.Y., Batrakova E.V., Kabanov A.V. Hypersensitization of multidrug resistant human ovarian carcinoma cells by Pluronic P85 block copolymer. Bioconjug. Chem. 7:1996;209-216.
4. Venne A., Li S., Mandeville R., Kabanov A., Alakhov V. Hypersensitizing effect of Pluronic L61 on cytotoxic activity, transport, and subcellular distribution of doxorubicin in multiple drug-resistant cells. Cancer Res. 56:1996;3626-3629.
5. Alakhov V., Klinski E., Li S., Pietrzynski G., Venne A., Batrakova E., Bronitch T., Kabanov A.V. Block copolymer-based formulation of doxorubicin. From cell screen to clinical trials. Colloids Surf. B: Biointerfaces. 16:1999;113-134.
6. Stolnik S., Illum L., Davis S.S. Long circulating microparticulate drug carriers. Adv. Drug. Deliv. Rev. 16:1995;195-214.
7. Schmolka I.R. A review of block polymer surfactants. J. Am. Oil Chem. Soc. 54:1977;110-116.
8. Geyer R.P. Perfluorochemicals as oxygen transport vehicles. Biomater. Artif. Cells Artif. Organs. 16:1988;31-49.
9. Allison A.C., Byars N.E. Adjuvant formulations and their mode of action. Semin. Immunol. 2:1990;369-374.
10. Schmolka I.R. Physical basis for poloxamer interactions. Ann. NY Acad. Sci. 720:1994;92-97.
11. Hawley A.E., Davis S.S., Illum L. Targeting of colloids to lymph nodes: influence of lymphatic physiology and colloidal characteristics. Adv. Drug. Deliv. Rev. 17:1995;129-148.
12. Newman M.J., Actor J.K., Balusubramanian M., Jagannath C. Use of non-ionic block copolymers in vaccines and therapeutics. Crit. Rev. Ther. Drug Carrier Syst. 15:1998;89-142.
13. Malmsten M. Block copolymers in pharmaceutics. Alexandridis P., Lindman B. Amphiphilic Block Copolymers: Self Assembly and Applications. 2000;319-346 Elsevier, Amsterdam.
14. Moghimi S.M., Hunter A.C. Poloxamers and poloxamines in nanoparticle engineering and experimental medicine. Trends Biotechnol. 18:2000;412-420.
15. Anderson B.C., Pandit N.K., Mallapragada S.K. Understanding drug release from poly(ethylene oxide)-b-poly(propylene oxide)-b-poly(ethylene oxide) gels. J. Controlled Release. 70:2001;157-167.
16. Kabanov A.V., Alakhov V. Pluronic block copolymers in drug delivery: from micellar nanocontainers to biological response modifiers. Crit. Rev. Ther. Drug Carrier Syst. 19:2002;1-73.
17. Pifferi G., Santoro P., Pedrani M. Quality and functionality of excipients. Farmaco. 54:1999;1-14.
18. Allison A.C., Byars N.E. Adjuvant formulations and their mode of action. Semin. Immunol. 2:1990;369-374.
19. Bomford R. The adjuvant activity of fatty acid esters. The role of acyl chain length and degree of saturation. Immunology. 44:1981;187-192.
20. Hunter R.L., McNicholl J., Lal A.A. Mechanisms of action of non-ionic block copolymer adjuvants. AIDS Res. Hum. Retroviruses. 10:1994;S95-S98.
21. Hunter R., Olsen M., Buynitzky S. Adjuvant activity of non-ionic block copolymers. IV. Effect of molecular weight and formulation on titre and isotype of antibody. Vaccine. 9:1991;250-256.
22. Hunter R., Strickland F., Kezdy F. The adjuvant activity of non-ionic block polymer surfactants. I. The role of hydrophile-lipophile balance. J. Immunol. 127:1981;1244-1250.
23. Hunter R.L., Bennett B. The adjuvant activity of non-ionic block polymer surfactants. II. Antibody formation and inflammation related to the structure of triblock and octablock copolymers. J. Immunol. 133:1984;3167-3175.
24. Hunter R.L., Bennett B. The adjuvant activity of non-ionic block polymer surfactants. III. Characterization of selected biologically active surfaces. Scand. J. Immunol. 23:1986;287-300.
25. Allison A.C., Byars N.E. An adjuvant formulation that selectively elicits the formation of antibodies of protective isotypes and of cell-mediated immunity. J. Immunol. Methods. 95:1986;157-168.
26. Byars N.E., Allison A.C. Adjuvant formulation for use in vaccines to elicit both cell-mediated and humoral immunity. Vaccine. 5:1987;223-228.
27. Ke Y., McGraw C.L., Hunter R.L., Kapp J.A. Non-ionic triblock copolymers facilitate delivery of exogenous proteins into the MHC class I and class II processing pathways. Cell. Immunol. 176:1997;113-121.
28. Millet P., Kalish M.L., Collins W.E., Hunter R.L. Effect of adjuvant formulations on the selection of B-cell epitopes expressed by a malaria peptide vaccine. Vaccine. 10:1992;547-550.
29. Takayama K., Olsen M., Datta P., Hunter R.L. Adjuvant activity of non-ionic block copolymers. V. Modulation of antibody isotype by lipopolysaccharides, lipid A and precursors. Vaccine. 9:1991;257-265.
30. Schmolka I.R. Artificial skin. I. Preparation and properties of Pluronic F-127 gels for treatment of burns. J. Biomed. Mater. Res. 6:1972;571-582.
31. Rodeheaver G., Turnbull V., Edgerton M.T., Kurtz L., Edlich R.F. Pharmacokinetics of a new skin wound cleanser. Am. J. Surg. 132:1976;67-74.
32. Rodeheaver G.T., Kurtz L., Kircher B.J., Edlich R.F. Pluronic F-68: a promising new skin wound cleanser. Ann. Emerg. Med. 9:1980;572-576.
33. Nalbandian R.M., Henry R.L., Balko K.W., Adams D.V., Neuman N.R. Pluronic F-127 gel preparation as an artificial skin in the treatment of third-degree burns in pigs. J. Biomed. Mater. Res. 21:1987;1135-1148.
34. Gear A.J., Hellewell T.B., Wright H.R., Mazzarese P.M., Arnold P.B., Rodeheaver G.T., Edlich R.F. A new silver sulfadiazine water soluble gel. Burns. 23:1997;387-391.
35. Follis F., Jenson B., Blisard K., Hall E., Wong R., Kessler R., Temes T., Wernly J. Role of poloxamer 188 during recovery from ischemic spinal cord injury: a preliminary study. J. Invest. Surg. 9:1996;149-156.
36. Agren M.S. An amorphous hydrogel enhances epithelialisation of wounds. Acta Derm. Venereol. 78:1998;119-122.
37. Cao Y.L., Lach E., Kim T.H., Rodriguez A., Arevalo C.A., Vacanti C.A. Tissue-engineered nipple reconstruction. Plast. Reconstr. Surg. 102:1998;2293-2298.
38. Batrakova E.V., Lee S., Li S., Venne A., Alakhov V., Kabanov A. Fundamental relationships between the composition of Pluronic block copolymers and their hypersensitization effect in MDR cancer cells. Pharm. Res. 16:1999;1373-1379.
39. Batrakova E.V., Li S., Elmquist W.F., Miller D.W., Alakhov V.Y., Kabanov A.V. Mechanism of sensitization of MDR cancer cells by Pluronic block copolymers: selective energy depletion. Br. J. Cancer. 85:2001;1987-1997.
40. Batrakova E.V., et al. Anthracycline antibiotics non-covalently incorporated into the block copolymer micelles: in vivo evaluation of anti-cancer activity. Br. J. Cancer. 74:1996;1545-1552.
41. Ranson M., Ferry D., Kerr D., Radford J., Dickens D., Alakhov V., Brampton M., Margison J. Results of a cancer research campaign phase I dose escalation trial of SP1049C in patients with advanced cancer. The 5th International Symposium on Polymer Therapeutics: From Laboratory to Clinical Practice. 2002;15 The Welsh School of Pharmacy, Cardiff University, Cardiff, UK.
42. Kabanov A.V., Batrakova E.V., Alakhov V. Pluronic block copolymers for overcoming drug resistance in cancer. Adv. Drug Deliv. Rev. 54:2002;759-779.
43. Woodcock D.M., Jefferson S., Linsenmeyer M.E., Crowther P.J., Chojnowski G.M., Williams B., Bertoncello I. Reversal of the multidrug resistance phenotype with cremophor EL, a common vehicle for water-insoluble vitamins and drugs. Cancer Res. 50:1990;4199-4203.
44. Woodcock D.M., Linsenmeyer M.E., Chojnowski G., Kriegler A.B., Nink V., Webster L.K., Sawyer W.H. Reversal of multidrug resistance by surfactants. Br. J. Cancer. 66:1992;62-68.
45. Dudeja P.K., Anderson K.M., Harris J.S., Buckingham L., Coon J.S. Reversal of multidrug resistance phenotype by surfactants: relationship to membrane lipid fluidity. Arch. Biochem. Biophys. 319:1995;309-315.
46. Buckingham L.E., Balasubramanian M., Emanuele R.M., Clodfelter K.E., Coon J.S. Comparison of solutol HS 15, Cremophor EL and novel ethoxylated fatty acid surfactants as multidrug resistance modification agents. Int. J. Cancer. 62:1995;436-442.
47. Miller D.W., Batrakova E.V., Waltner T.O., Alakhov V., Kabanov A.V. Interactions of Pluronic block copolymers with brain microvessel endothelial cells: evidence of two potential pathways for drug absorption. Bioconjug. Chem. 8:1997;649-657.
48. Batrakova E.V., Han H.Y., Alakhov V., Miller D.W., Kabanov A.V. Effects of Pluronic block copolymers on drug absorption in Caco-2 cell monolayers. Pharm. Res. 15:1998;850-855.
49. Batrakova E.V., Miller D.W., Li S., Alakhov V.Y., Kabanov A.V., Elmquist W.F. Pluronic P85 enhances the delivery of digoxin to the brain: in vitro and in vivo studies. J. Pharmacol. Exp. Ther. 296:2001;551-557.
50. 32 P]ATP. Biochem. Int. 26:1992;587-595.
51. Kirillova G.P., Mokhova E.N., Dedukhova V.I., Tarakanova A.N., Ivanova V.P., Efremova N.V., Topchieva I.N. The influence of pluronics and their conjugates with proteins on the rate of oxygen consumption by liver mitochondria and thymus lymphocytes. Biotechnol. Appl. Biochem. 18:1993;329-339.
52. Batrakova E.V., Li S., Vinogradov S.V., Alakhov V.Y., Miller D.W., Kabanov A.V. Mechanism of Pluronic effect on p-glycoprotein efflux system in blood-brain barrier: contributions of energy depletion and membrane fluidization. J. Pharmacol. Exp. Ther. 299:2001;483-493.
53. Batrakova E.V., Han H.Y., Miller D.W., Kabanov A.V. Effects of Pluronic P85 unimers and micelles on drug permeability in polarized BBMEC and Caco-2 cells. Pharm. Res. 15:1998;1525-1532.
54. Melik-Nubarov N.S., Pomaz O.O., Dorodnych T., Badun G.A., Ksenofontov A.L., Schemchukova O.B., Arzhakov S.A. Interaction of tumor and normal blood cells with ethylene oxide and propylene oxide block copolymers. FEBS Lett. 446:1999;194-198.
55. Regev R., Assaraf Y.G., Eytan G.D. Membrane fluidization by ether, other anesthetics, and certain agents abolishes P-glycoprotein ATPase activity and modulates efflux from multidrug-resistant cells. Eur. J. Biochem. 259:1999;18-24.
56. Nerurkar M.M., Burton P.S., Borchardt R.T. The use of surfactants to enhance the permeability of peptides through Caco-2 cells by inhibition of an apically polarized efflux system. Pharm. Res. 13:1996;528-534.
57. Nerurkar M.M., Ho N.F., Burton P.S., Vidmar T.J., Borchardt R.T. Mechanistic roles of neutral surfactants on concurrent polarized and passive membrane transport of a model peptide in Caco-2 cells. J. Pharm. Sci. 86:1997;813-821.
58. Rapoport N., Marin A.P., Timoshin A.A. Effect of a polymeric surfactant on electron transport in HL-60 cells. Arch. Biochem. Biophys. 384:2000;100-108.
59. Batrakova E.V., Li S., Miller D.W., Kabanov A.V. Pluronic P85 increases permeability of a broad spectrum of drugs in polarized BBMEC and Caco-2 cell monolayers. Pharm. Res. 16:1999;1366-1372.
60. Huai-Yun H., Secrest D.T., Mark K.S., Carney D., Brandquist C., Elmquist W.F., Miller D.W. Expression of multidrug resistance-associated protein (MRP) in brain microvessel endothelial cells. Biochem. Biophys. Res. Commun. 243:1998;816-820.
61. Borst P., Evers R., Kool M., Wijnholds J. A family of drug transporters: the multidrug resistance-associated proteins. J. Natl. Cancer Inst. 92:2000;1295-1302.
62. Miller D.W., Batrakova E.V., Kabanov A.V. Inhibition of multidrug resistance-associated protein (MRP) functional activity with Pluronic block copolymers. Pharm. Res. 16:1999;396-401.
63. Kabanov A.V., et al. The neuroleptic activity of haloperidol increases after its solubilization in surfactant micelles. Micelles as microcontainers for drug targeting. FEBS Lett. 258:1989;343-345.
64. Kabanov A.V., et al. A new class of drug carriers: micelles of poly(oxyethylene)-poly(oxypropylene) block copolymers as microcontainers for drug targeting from blood in brain. J. Controlled Release. 22:1992;141-157.
65. Kawahara M., Sakata A., Miyashita T., Tamai I., Tsuji A. Physiologically based pharmacokinetics of digoxin in mdr1a knockout mice. J. Pharm. Sci. 88:1999;1281-1287.
66. Moghimi S.M., Hunter A.C. Poloxamers and poloxamines in nanoparticle engineering and experimental medicine. Trends Biotechnol. 18:2000;412-420.
67. Schaer G.L., et al. Beneficial effects of RheothRx injection in patients receiving thrombolytic therapy for acute myocardial infarction. Results of a randomized, double-blind, placebo-controlled trial. Circulation. 94:1996;298-307.
68. Toth K., Bogar L., Juricskay I., Keltai M., Yusuf S., Haywood L.J., Meiselman H.J. The effect of RheothRx injection on the hemorheological parameters in patients with acute myocardial infarction. Clin. Hemorheol. Microcirc. 17:1997;117-125.
69. Palmer W.K., Emeson E.E., Johnston T.P. Poloxamer 407-induced atherogenesis in the C57BL/6 mouse. Atherosclerosis. 136:1998;115-123.
70. Wout Z.G., Pec E.A., Maggiore J.A., Williams R.H., Palicharla P., Johnston T.P. Poloxamer 407-mediated changes in plasma cholesterol and triglycerides following intraperitoneal injection to rats. J. Parenter. Sci. Technol. 46:1992;192-200.
71. Blonder J.M., Baird L., Fulfs J.C., Rosenthal G.J. Dose-dependent hyperlipidemia in rabbits following administration of poloxamer 407 gel. Life Sci. 65:1999;L261-L266.
72. Kabanov A.V., Nazarova I.R., Astafieva I.V., Batrakova E.V., Alakhov V.Y., Yaroslavov A.A., et al. Micelle formation and solubilization of fluorescent probes in poly(oxyethylene-b-oxypropelene-b-oxyethylene) solutions. Macromolecules. 28:1995;2303-2314.